Next-Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematological Malignancies

Leukemia - United Kingdom
doi 10.1038/leu.2016.136
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Next Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Minimal Residual Disease Monitoring With Next-Generation Sequencing Methodologies in Hematological Malignancies

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Improved Outcome of Critically Ill Patients With Hematological Malignancies: What’s Next?

Intensive Care Medicine
Critical CareIntensive Care Medicine
2014English

Ih2 Inhibition Enhances Proteasome Inhibitor Responsiveness in Hematological Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Improved Efficacy of a Next-Generation ERT in Murine Pompe Disease

JCI insight
Medicine
2019English

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery
Oncology
2013English

In Vivo Cellular Reprogramming: The Next Generation

Cell
BiochemistryGeneticsMolecular Biology
2016English

Telomerase Activation in Hematological Malignancies

Genes
Genetics
2016English

Bridging the Gap in Hematological Malignancies

Expert Review of Hematology
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy